SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending after reporting robust earnings and strong guidance driven by its booming data center and AI segments, yet community discussion is polarized between long-term bullish conviction in its AI leadership and concerns over the muted stock reaction, high valuation, and options expiring worthless amid perceived market manipulation.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is trending as the community celebrates a significant earnings and revenue beat, fueling expectations of continued growth driven by the Alani Nu acquisition and expanding PepsiCo partnership. Investors are actively discussing the potential for the stock to be "Monster 2.0" and reach new highs as it gains substantial shelf space.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is trending after its earnings report delivered a revenue and EPS beat, but its weaker-than-expected Q1 guidance triggered a significant share price decline and a Loop Capital downgrade. Community sentiment is split, with many investors decrying perceived management missteps and market manipulation, while others view the substantial dip as an attractive entry point for a fundamentally sound, oversold company.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending after delivering financial results that significantly surpassed expectations, fueling community discussion about a potential short squeeze and the strategic implications of its recent SkyWater acquisition. The market is actively debating its strong revenue growth and ambitious quantum computing roadmap against continuing profitability challenges.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as investors eagerly await its upcoming earnings report for crucial updates on the AUR200 pipeline, with extensive community discussion fueled by ongoing frustration with management's communication and heightened speculation of a potential acquisition.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum Inc. (QBTS) is intensely discussed ahead of its earnings report, with optimism fueled by recent government and enterprise contract wins, coupled with the CEO's claims of immediate real-world applications for its dual-platform quantum technology, particularly in defense. However, community debate persists regarding the stock's high valuation and the quantum sector's timeline to consistent profitability.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy is seeing intense debate ahead of its Q4 earnings report, with bullish investors anticipating significant growth from new large-scale project wins and the surging demand for grid-scale energy storage, particularly for AI data centers, while others remain wary of past performance.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce (CRM) is trending after exceeding earnings expectations and announcing a significant new share repurchase program, sparking a tug-of-war between bulls who see deep value and future EPS growth, and bears concerned about long-term growth prospects amidst pervasive AI disruption fears in the software sector.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is surging as robust financial results, including a boosted profit outlook and plans for significant shareholder returns, drive community enthusiasm for its remarkable turnaround and diversified growth in defense, SMRs, and civil aerospace.

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Larimar Therapeutics is trending after its Friedreich's ataxia drug, nomlabofusp, received FDA Breakthrough Therapy Designation, leading to a significant rally followed by an upsized $100 million stock offering at $5 per share. Bulls are excited about the accelerated approval pathway and potential blockbuster status, citing analyst upgrades and anticipating a short squeeze, while bears emphasize dilution concerns, the company's lack of revenue, and high debt.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SGMO We can all thank Vinay Prasad in large part for keeping our share price in the dumps despite promising Fabry data and an FDA-endorsed pathway to accelerated approval. This is from today WSJ op-ed about the FDA... 
 
&quot;Food and Drug Administration chief Marty Makary boasted on these pages Monday about a new effort to allow more flexible reviews for drugs treating rare diseases. A good idea. But is the Commissioner paying attention to what his biologics chief Vinay Prasad is doing that conflicts with this goal? 
 
That’s the operating contradiction at FDA, after the agency this month rejected two rare disease drugs seeking accelerated approval. Congress in 2012 enacted the accelerated approval pathway to fast-track medicines that treat life-threatening diseases. Dr. Prasad is quietly undermining the program.&quot; 
https://www.wsj.com/opinion/vinay-prasad-fda-drug-approvals-disc-medicine-regenxbio-marty-makary-8488f514?mod=trending_now_opn_3